A case series of adrenoleukodystrophy in children conceived through in vitro fertilization with an egg donor
Crystal Chang, B.S.,
Ashish O. Gupta, M.B.B.S., M.P.H.,
Paul J. Orchard, M.D.,
David R. Nascene, M.D.,
Janell Kierstein, M.S.,
Rebecca K. Tryon, M.S., M.A.,
Troy C. Lund, M.D., Ph.D.
Affiliations
Crystal Chang, B.S.
Division of Pediatric Blood and Marrow Transplantation and Cellular Therapy Program, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota
Ashish O. Gupta, M.B.B.S., M.P.H.
Division of Pediatric Blood and Marrow Transplantation and Cellular Therapy Program, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota
Paul J. Orchard, M.D.
Division of Pediatric Blood and Marrow Transplantation and Cellular Therapy Program, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota
David R. Nascene, M.D.
Department of Radiology, University of Minnesota Medical School, Minneapolis, Minnesota
Janell Kierstein, M.S.
Department of Genetics and Metabolism, Children’s Hospital Colorado, Aurora, Colorado
Rebecca K. Tryon, M.S., M.A.
Division of Pediatric Blood and Marrow Transplantation and Cellular Therapy Program, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota; Department of Genetics, M Health Fairview, Minneapolis, Minnesota
Troy C. Lund, M.D., Ph.D.
Division of Pediatric Blood and Marrow Transplantation and Cellular Therapy Program, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota; Reprint requests: Troy C. Lund, M.D., Ph.D., Division of Pediatric Blood and Marrow Transplant, Metabolic Program, University of Minnesota, 420 Delaware St SE, Minneapolis, Minnesota 55455.
Objective: To report 3 cases of adrenoleukodystrophy (ALD) in children conceived by in vitro fertilization (IVF) and egg donation. Design: A case report. Patient(s): Patients aged 4–5 years old, evaluated by the University of Minnesota Leukodystrophy Center, who were diagnosed with ALD after being conceived by IVF with oocytes provided by the same donor. Intervention(s): One patient received a hematopoietic stem cell transplant from a human leukocyte antigen-matched donor, and 1 patient received autologous lentiviral corrected hematopoietic cells. The disease state in 1 patient was unfortunately too advanced for effective treatment to be administered. Main Outcome Measure(s): Progression of disease after diagnosis or treatment was observed by cerebral magnetic resonance imaging and monitoring the development or advancement of any cognitive, adaptive, and motor deficits. Result(s): Patients who received a transplant for ALD successfully experienced little to no disease progression at least 6 months to 1 year after treatment. Conclusion(s): These 3 cases of transmission of ALD through oocyte donation and IVF highlight the potential need to implement more comprehensive genetic screening of gamete donors to prevent the transfer of rare but severe genetic diseases through IVF. Further, these cases highlight limitations in carrier screening guidelines that limit reportable variants to pathogenic and likely pathogenic variants.
